Closest look yet at killer T-cell activity could yield new approach to tackling antibiotic resistance

In a study that could provide a roadmap for combatting the rising threat of drug-resistant pathogens, researchers have discovered the specific mechanism the body’s T cells use to kill bacteria.

University of Michigan researchers, in collaboration with colleagues at Harvard University, have discovered a key difference between the way immune cells attack bacteria and the way antibiotics do. Where drugs typically attack a single process within bacteria, T cells attack a host of processes at the same time.

Today, the journal Cell published findings from a team headed by U-M’s Sriram Chandrasekaran and Harvard’s Judy Lieberman. It’s a study with potential implications for drug-resistant pathogens—a problem projected to kill as many as 10 million people annually across the globe by the year 2050.

“We have a huge crisis of antibiotic resistance right now in that most drugs that treat diseases like tuberculosis or listeria, or pathogens like E.coli, are not effective,” said Chandrasekaran, U-M assistant professor of biomedical engineering. “So there is a huge need for figuring out how the immune system does its work. We hope to design a drug that goes after bacteria in a similar way.”

Killer T cells, formally known as cytotoxic lymphocytes, attack infected cells by producing the enzyme granzyme B. How this enzyme triggers death in bacteria has not been well understood, Chandrasekaran said.

Proteomics—a technique that measures protein levels in a cell—and computer modeling, allowed researchers to see granzyme B’s multipronged attack targeting multiple processes.

Chandrasekaran and his team monitored how T cells deal with three different threats: E. coli, listeria and tuberculosis.

“When exposed to granzyme B, the bacteria were unable to develop resistance to the multipronged attack, even after exposure over multiple generations,” Chandrasekaran said. “This enzyme breaks down multiple proteins that are essential for the bacteria to survive. It’s essentially killing several birds with one stone.”

The possible applications of the new findings on T cells run the gamut from the creation of new medications to the repurposing of previously approved drugs in combination to fight infections by mimicking granzyme B.

Chandrasekaran’s team is now looking at how bacteria hide to avoid T-cell attacks.

And the need for a new approach in some form is dire. World Health Organization officials describe antibiotic resistance as “one of the biggest threats to global health, food security and development today.”

Each year, an estimated 700,000 deaths are linked to antibiotic-resistant bacteria, according to the WHO. Projections show that number skyrocketing to 10 million by 2050.

England’s top health official, Sally Davies, recently said the lost effectiveness of antibiotics would mean “the end of modern medicine.”

“We really are facing—if we don’t take action now—a dreadful post-antibiotic apocalypse,” she was quoted saying earlier this month. “I don’t want to say to my children that I didn’t do my best to protect them and their children.”

Of particular concern is the fact that there are few new antibiotics in the pipeline. The heyday of new antibiotics occurred in the 1940s through the 1960s, with releases eventually grinding almost to a halt by the end of the 20th century.

“We’ve reached a point where we take what antibiotics can do for granted, and we can’t do that anymore,” Chandrasekaran said. “We’re taking inspiration from the human immune system, which has been fighting infections for thousands of years.”

The paper is titled, “Granzyme B disrupts central metabolism and protein synthesis in bacteria to promote an immune cell death program.” The research is funded by the National Institutes of Health, Harvard University and the University of Michigan.

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.

9 thoughts on “Closest look yet at killer T-cell activity could yield new approach to tackling antibiotic resistance”

  1. I truly wanted to write down a small note so as to express gratitude
    to you for the marvelous information you are placing on this site.
    My incredibly long internet lookup has at the end of the day been compensated with reliable insight to
    exchange with my two friends. I ‘d suppose that we site visitors actually are truly endowed to dwell in a fine website with many special individuals
    with great secrets. I feel pretty lucky to have encountered the webpage and look forward
    to plenty of more pleasurable times reading here. Thank you once again for everything.

  2. I’d like to thank you for the efforts you have put in penning this site.
    I really hope to view the same high-grade content by you later on as
    well. In truth, your creative writing abilities has motivated
    me to get my own site now ;)

  3. Hi, this weekend is pleasant for me, for the reason that this occasion i am reading this fantastic educational article here at my house.

  4. Merely to follow up on the update of this topic on your website and would like to
    let you know how much I valued the time you took to put together this valuable post.
    Within the post, you spoke of how to definitely handle this thing with all comfort.
    It would be my pleasure to get together some more strategies from your web-site and come as much as offer people what I learned
    from you. Thank you for your usual wonderful effort.

  5. Thanks so much for giving everyone an exceptionally special opportunity to read critical reviews from here.
    It’s always very lovely and as well , jam-packed with a lot of fun for
    me personally and my office friends to search your blog
    a minimum of thrice in 7 days to see the latest guides you have.
    And indeed, I’m so usually fascinated with all the
    eye-popping knowledge you serve. Certain 3 ideas in this posting are clearly the finest we have
    ever had.

Comments are closed.